Joshua D. Rosenblat, MD, MSc, FRCPC

Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada

JCP
Global Population-Based Study on the Association Between Ketamine and Esketamine with Suicidality Using WHO VigiBase
Original Research

July 7, 2025

The results do not provide causal evidence of worsening suicidality in persons receiving esketamine/ketamine; mixed results of increased and decreased risk of suicidality were reported with both agents.
, , , et al
JCP
What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?
ASCP Corner

June 2, 2025

The authors encourage the field to destigmatize the term “deprescribing” from its misappropriated usage, explicate its accurate definition, and reclaim its purposeful meaning.
, , , et al
JCP
Correction

April 22, 2020

, , , et al
JCP
Letter to the Editor

January 28, 2020

 Rosenblat and McIntyre reply to the letter "Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?" by Swainson and Khullar.
,
JCP
Review Article

April 16, 2019

Intravenous ketamine has rapid and robust antidepressant effects. Read this systematic review to learn if oral ketamine also has efficacy and tolerability in depressed individuals.
, , , et al
PCC
Article

November 1, 2018

What patient-reported factors influence medication treatment decisions among individuals with bipolar and unipolar depression? The authors of this article conducted a survey to answer this question. Their findings may...
, , , et al
JCP
Review Article

June 28, 2017

In theory, pharmacogenomic testing in patients with depression can improve clinical outcomes by guiding antidepressant selection and dosing. This review looks at the current evidence to evaluate the clinical...
, ,

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe